



Zomig® (zolmitriptan) – First-time authorized brand alternative

- On January 19, 2021, Amneal launched an authorized brand alternative of Amneal Specialty's [Zomig \(zolmitriptan\)](#) nasal spray.
- Zomig nasal spray is approved for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.
- Zomig is also available generically as a [tablet](#) and [orally disintegrating tablet \(ODT\)](#).
 - The tablet and ODT are indicated for the acute treatment of migraine with or without aura in adults.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.